Emergent BioSolutions Inc (EBS)
6.175
+0.14
(+2.24%)
USD |
NYSE |
Jun 14, 16:00
6.175
0.00 (0.00%)
After-Hours: 20:00
Emergent BioSolutions Accounts Receivable (Quarterly): 194.10M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 194.10M |
December 31, 2023 | 141.80M |
September 30, 2023 | 156.60M |
June 30, 2023 | 238.50M |
March 31, 2023 | 106.50M |
December 31, 2022 | 102.70M |
September 30, 2022 | 119.00M |
June 30, 2022 | 119.90M |
March 31, 2022 | 115.20M |
December 31, 2021 | 230.50M |
September 30, 2021 | 197.00M |
June 30, 2021 | 210.30M |
March 31, 2021 | 134.00M |
December 31, 2020 | 172.70M |
September 30, 2020 | 166.00M |
June 30, 2020 | 202.20M |
March 31, 2020 | 119.40M |
December 31, 2019 | 227.30M |
September 30, 2019 | 251.40M |
June 30, 2019 | 179.50M |
March 31, 2019 | 89.60M |
December 31, 2018 | 234.00M |
September 30, 2018 | 76.96M |
June 30, 2018 | 189.49M |
March 31, 2018 | 122.09M |
Date | Value |
---|---|
December 31, 2017 | 118.90M |
September 30, 2017 | 129.36M |
June 30, 2017 | 102.51M |
March 31, 2017 | 128.08M |
December 31, 2016 | 90.44M |
September 30, 2016 | 69.63M |
June 30, 2016 | 66.75M |
March 31, 2016 | 69.56M |
December 31, 2015 | 95.74M |
September 30, 2015 | 57.04M |
June 30, 2015 | 99.72M |
March 31, 2015 | 64.06M |
December 31, 2014 | 39.95M |
September 30, 2014 | 44.11M |
June 30, 2014 | 78.27M |
March 31, 2014 | 62.94M |
December 31, 2013 | 45.76M |
September 30, 2013 | 30.09M |
June 30, 2013 | 54.37M |
March 31, 2013 | 62.96M |
December 31, 2012 | 76.16M |
September 30, 2012 | 17.08M |
June 30, 2012 | 46.82M |
March 31, 2012 | 43.65M |
December 31, 2011 | 55.19M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
102.70M
Minimum
Dec 2022
251.40M
Maximum
Sep 2019
169.23M
Average
169.35M
Median
Accounts Receivable (Quarterly) Benchmarks
FibroGen Inc | 37.08M |
Geron Corp | -- |
Macrogenics Inc | 7.219M |
Verrica Pharmaceuticals Inc | 7.002M |
Recursion Pharmaceuticals Inc | -- |